within Pharmacolibrary.Drugs.ATC.L;

model L04AF05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.8383333333333333,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.175,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Itacitinib is an oral, selective inhibitor of Janus kinase 1 (JAK1) developed for the treatment of graft-versus-host disease (GVHD) and hematological malignancies. While itacitinib has undergone several clinical trials, it is not currently FDA-approved for any indication as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with hematological malignancies and healthy volunteers. Data reflect single and multiple oral doses in clinical studies.</p><h4>References</h4><ol><li><p>Barbour, AM, et al., &amp; Yeleswaram, S (2019). Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects. <i>Journal of clinical pharmacology</i> 59(12) 1641–1647. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1484&quot;>10.1002/jcph.1484</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31282592/&quot;>https://pubmed.ncbi.nlm.nih.gov/31282592</a></p></li><li><p>Covington, M, et al., &amp; Smith, P (2020). Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases. <i>European journal of pharmacology</i> 885 173505–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejphar.2020.173505&quot;>10.1016/j.ejphar.2020.173505</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32861662/&quot;>https://pubmed.ncbi.nlm.nih.gov/32861662</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AF05;
